These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2000 related articles for article (PubMed ID: 33941925)

  • 21. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
    Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
    Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses.
    Bullen G; Galson JD; Hall G; Villar P; Moreels L; Ledsgaard L; Mattiuzzo G; Bentley EM; Masters EW; Tang D; Millett S; Tongue D; Brown R; Diamantopoulos I; Parthiban K; Tebbutt C; Leah R; Chaitanya K; Ergueta-Carballo S; Pazeraitis D; Surade SB; Ashiru O; Crippa L; Cowan R; Bowler MW; Campbell JI; Lee WJ; Carr MD; Matthews D; Pfeffer P; Hufton SE; Sawmynaden K; Osbourn J; McCafferty J; Karatt-Vellatt A
    Front Immunol; 2021; 12():678570. PubMed ID: 34211469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flawed interferon response spurs severe illness.
    Wadman M
    Science; 2020 Sep; 369(6511):1550-1551. PubMed ID: 32973008
    [No Abstract]   [Full Text] [Related]  

  • 24. Upper age limits for convalescent plasma donation and treatment of COVID-19 patients: A further marker of ageism.
    Fedecostante M; O'Neill D; Pierri F; Carrieri B; Lattanzio F; Cherubini A
    Transfusion; 2021 Sep; 61(9):2799-2800. PubMed ID: 34227110
    [No Abstract]   [Full Text] [Related]  

  • 25. Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.
    Franchini M; Mengoli C; Ballotari A; Glingani C
    Transfus Clin Biol; 2022 May; 29(2):186-187. PubMed ID: 34690072
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
    Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
    Donato ML; Park S; Baker M; Korngold R; Morawski A; Geng X; Tan M; Ip A; Goldberg S; Rowley S; Chow K; Brown E; Zenreich J; McKiernan P; Buttner K; Ullrich A; Long L; Feinman R; Ricourt A; Kemp M; Vendivil M; Suh H; Balani B; Cicogna C; Sebti R; Al-Khan A; Sperber S; Desai S; Fanning S; Arad D; Go R; Tam E; Rose K; Sadikot S; Siegel D; Gutierrez M; Feldman T; Goy A; Pecora A; Biran N; Leslie L; Gillio A; Timmapuri S; Boonstra M; Singer S; Kaur S; Richards E; Perlin DS
    JCI Insight; 2021 Mar; 6(6):. PubMed ID: 33571168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.
    Betrains A; Godinas L; Woei-A-Jin FJSH; Rosseels W; Van Herck Y; Lorent N; Dierickx D; Compernolle V; Meyfroidt G; Vanderbeke L; Vergote V; Lagrou K; Verhamme P; Wauters J; Vermeersch P; Devos T; Maes P; Vanderschueren S
    Br J Haematol; 2021 Mar; 192(6):1100-1105. PubMed ID: 33314018
    [No Abstract]   [Full Text] [Related]  

  • 29. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
    Prus K; Alquist CR; Cancelas JA; Oh D
    Transfusion; 2021 Feb; 61(2):651-654. PubMed ID: 33616966
    [No Abstract]   [Full Text] [Related]  

  • 30. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
    Zou J; Li L; Zheng P; Liang W; Hu S; Zhou S; Wang Y; Zhao J; Yuan D; Liu L; Wu D; Xu M; Zhang F; Zhu M; Wu Z; Cao X; Ni M; Ling X; Wu Y; Kuang Z; Hu M; Li J; Li X; Guo X; Xu T; Jiang H; Gao C; Yu M; Liu J; Zhong N; Zhou J; Huang JA; Jin T; He J
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35108220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
    Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Audio Interview: Aspects of Covid-19 Immunity.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Aug; 385(8):e31. PubMed ID: 34407350
    [No Abstract]   [Full Text] [Related]  

  • 34. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.
    Aviani JK; Halim D; Soeroto AY; Achmad TH; Djuwantono T
    Rev Med Virol; 2021 Nov; 31(6):e2225. PubMed ID: 33621405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.
    Jahrsdörfer B; Groß R; Seidel A; Wettstein L; Ludwig C; Schwarz T; Körper S; Rojewski M; Lotfi R; Weinstock C; Seifried E; Corman VM; Drosten C; Münch J; Schrezenmeier H
    J Immunol; 2021 Jun; 206(11):2614-2622. PubMed ID: 33980583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
    Vazquez SE; Bastard P; Kelly K; Gervais A; Norris PJ; Dumont LJ; Casanova JL; Anderson MS; DeRisi JL
    J Clin Immunol; 2021 Aug; 41(6):1169-1171. PubMed ID: 34009544
    [No Abstract]   [Full Text] [Related]  

  • 37. Neutralizing antibody: a savior in the Covid-19 disease.
    Gupta SL; Jaiswal RK
    Mol Biol Rep; 2022 Mar; 49(3):2465-2474. PubMed ID: 34988889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ESC: a comprehensive resource for SARS-CoV-2 immune escape variants.
    Rophina M; Pandhare K; Shamnath A; Imran M; Jolly B; Scaria V
    Nucleic Acids Res; 2022 Jan; 50(D1):D771-D776. PubMed ID: 34643704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 100.